Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | BI 905677 |
Synonyms | |
Therapy Description |
BI 905677 is an antagonistic antibody that binds to LRP5 and LRP6 and inhibits Wnt signaling, potentially resulting in anti-tumor activity (Cancer Res 2019;79(13 Suppl):Abstract nr DDT01-01). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BI 905677 | BI-905677|BI905677|Anti-LRP5/6 Nanobody BI 905677 | BI 905677 is an antagonistic antibody that binds to LRP5 and LRP6 and inhibits Wnt signaling, potentially resulting in anti-tumor activity (Cancer Res 2019;79(13 Suppl):Abstract nr DDT01-01). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03604445 | Phase I | BI 905677 | This Study Aims to Find and Test a Safe Dose of BI 905677 in Patients With Different Types of Cancer (Solid Tumours) | Terminated | USA | NLD | ESP | 1 |